Skip to content
Alpha Edge Investing

Alpha Edge Investing

"Investors operate with limited funds and limited intelligence, they don’t need to know everything. As long as they understand better than others, they have an edge.” – George Soros

  • Home
  • Earnings Updates/ Corporate Actions
  • Research – Equities
  • Research – Fixed Income/ Bonds
  • Research – Unit Trust/ ETF
  • News
  • My Opinions/ Views
  • Others
  • About Me
  • Contact
  • Disclaimer
  • Community and Support Forums
  • Toggle search form

Maybank: Genting Singapore – Buy Target Price $0.85 (Previous $0.83)

Posted on July 23, 2022July 23, 2022 By alanyeo No Comments on Maybank: Genting Singapore – Buy Target Price $0.85 (Previous $0.83)

Marina Bay Sands post-Covid results encouraging

U/G to BUY with a higher TP of SGD0.85 (+2%)

Our read of Marina Bay Sands’ 2Q22 results is positive for GENS’ RWS. Operations recovered faster-than-expected even without Chinese gamblers. We lift FY22E earnings for GENS by 78%. While our long-term
earnings estimates are little changed, there is room for positive earnings revisions if China eases its zero-Covid policy. We tweak our DCF-based TP to SGD0.85 from SGD0.83. With >10% upside potential, we upgrade GENS to BUY from HOLD. GENS will report 2Q22 results on 12 Aug 2022.

MBS 2Q22 results buoyed by high VIP win rate…

Las Vegas Sands (LVS US, CP: USD37.08, Not Rated) released Marina Bay Sands (MBS) 2Q22 results this morning. These results are significant as they reflect operations after Singapore reopened its borders on 1 Apr 2022 and axed Covid-19 testing requirements on 26 Apr 2022. MBS’ 2Q22 EBITDA of USD319m was buoyed by a high VIP win rate of 4.29% (Fig. 1). Adjusted for a normal VIP win rate, MBS 2Q22 EBITDA came in at USD278m which was still the highest since the Covid-19 pandemic began.

… but underlying operations recovering fast

In USD terms, MBS’ 2Q22 VIP volume/mass market GGR recovered to 75%/92% of 2Q19 levels (Fig. 2 & 3) largely due to the return of Malaysian and Indonesian gamblers. Though a quarter earlier than we expected, they are broadly in-line with our expectation that industry VIP volume/mass market GGR will recover to 75%/85% of 2019 levels in the long term. LVS stated that gaming operations will not return to 100% of 2019 levels until China relaxes its zero-Covid policy.

Lift FY22E earnings by 78%

We advise investors not to draw 100% identical comparisons with RWS. RWS likely ceded market share, albeit to pre-Covid levels, as Singapore reopened its borders (Fig. 4). Yet, we gather that 2Q22 ought to be
sequentially much better for RWS. We lift FY22E earnings by 78% to account for an earlier recovery (2Q22 from 3Q22) (Fig. 5). While FY23E and FY24E earnings are little changed, there is room for positive
revisions should China ease its zero Covid policy.

Genting-SPClick here to Download Full Report in PDF

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
Research - Equities Tags:Genting SP

Post navigation

Previous Post: Edge: SATS record red ink of $22.5 million as it incurs higher costs to meet resumption of travel demand
Next Post: Bloomberg: Macau casinos reopen with dim business outlook amid travel curbs, as outlook for year calls for 35 per cent revenue drop

Related Posts

UOBKH: Gaming Singapore (Overweight) Research - Equities
UOBKH: Singapore Monthly Review and Outlook Research - Equities
UOBKH: STRATEGY – SINGAPORE Research - Equities
KGI: Genting Singapore (GENS SP) – “Rooms” are hot Research - Equities
DBS: Singapore Equity Picks – Guarding our performance 19 Sep 2022 Research - Equities
UOBKH: Singapore Strategy Research - Equities
OIR: Genting SP – Buy Target Price $0.92 Research - Equities
DBS: Genting Singapore – Buy Target Price $1.00 Research - Equities
UOBKH: Genting Singapore – Buy Target Price $1.08 Research - Equities
CIMB: Genting Singapore – Add Target Price $1.04 Research - Equities
UOBKH: Monthly Review and Outlook – Singapore Research - Equities
UOBKH: Singapore Strategy – Alpha Picks Research - Equities

Leave a Reply

You must be logged in to post a comment.

Login

Log In
Register Lost Password
Get new posts by email
Chat on WhatsApp
  • Earnings Updates/ Corporate Actions
  • My Opinions/ Views
  • News
  • Others
  • Research – Equities
  • Research – Fixed Income/ Bonds
  • Research – Unit Trusts/ ETF

Copyright © 2023 Alpha Edge Investing.

Powered by PressBook Grid Blogs theme